Free Alerts   Login
Health Care › Surgical and Medical Instruments And Apparatus

NVCR Stock Price Correlated With Novocure Financials

NVCR Stock Price vs. Quarterly
NVCR
Income Statement
Cash Flow
Balance Sheet

NVCR Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

NVCR Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

NVCR Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
FMR
15,962,767 sh
3,219 sh
0%
$238,324
-$19,423
Vanguard Group
9,759,098 sh
122,105 sh
1%
$145,704
-$9,933
Capital International Investors
8,861,871 sh
-142,621 sh
-2%
$132,308
-$13,119
Blackrock.
8,792,035 sh
929,654 sh
12%
$131,265
$4,288
Baillie Gifford
4,840,141 sh
-1,974,073 sh
-29%
$72,263
-$37,787
State Street
3,863,549 sh
1,770,927 sh
85%
$57,683
$23,887
Capital World Investors
3,276,996 sh
-5,601,735 sh
-63%
$48,926
-$94,468
Price T Rowe Associates /Md/
2,253,225 sh
-111,234 sh
-5%
$34
-$4
Two Sigma Advisers, Lp
1,634,500 sh
712,100 sh
77%
$24,403
$9,506
Geode Capital Management
1,591,963 sh
86,972 sh
6%
$23,772
-$538
Nordwand Advisors
1,515,000 sh
 
$22,619
Two Sigma Investments, Lp
1,470,464 sh
623,899 sh
74%
$21,954
$8,282
Voloridge Investment Management
1,426,724 sh
-279,864 sh
-16%
$21,301
-$6,260
Morgan Stanley
1,418,484 sh
328,864 sh
30%
$21,178
$3,580
D. E. Shaw & Co..
1,365,317 sh
1,013,867 sh
288%
$20,384
$14,708
Millennium Management
1,059,140 sh
1,048,440 sh
9799%
$15,813
$15,640
Norges Bank
974,050 sh
974,050 sh
NEW
$14,543
$14,543
Credit Suisse Ag
853,516 sh
28,557 sh
3%
$12,743
-$579
Frontier Capital Management Co
793,474 sh
369,037 sh
87%
$11,847
$4,992
Qube Research & Technologies
773,831 sh
773,831 sh
NEW
$11,553
$11,553
COMPANY PROFILE
ORGANIZATION AND BASIS OF PRESENTATION Organization . NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company currently markets Optune in the United States ("U.S."), Germany, Japan and certain other countries. The Company currently markets Optune Lua in the U.S. and European Union. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in China, Hong Kong, Macau and Taiwan ("Greater China"). See Note 12 to the Consolidated Financial Statements in the 2021 10-K.

During the year ended December 31, 2019, the Company implemented changes to its corporate entity operating structure, including transferring certain intellectual property to its Swiss subsidiary, primarily to align corporate entities with the Company’s evolving operations and business model. As of January 1, 2022, the effective place of daily management and control of the Company moved to Switzerland and the Company has become a Swiss tax resident.

Financial statement preparation . The accompanying unaudited consolidated financial statements include the accounts of the Company and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation for the periods presented. The preparation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 10-K") filed with the Securities and Exchange Commission on February 24, 2022.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2021 10-K are applied consistently in these unaudited interim consolidated financial statements, except as noted below:

Short-term investments

The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities."

Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies part of its debt securities as available-for-sale and the rest of the balance as held-to-maturity since the Company has the intent and ability to hold the securities to maturity.

Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sale of investments are included in financial income, net and are derived using the specific identification method for determining the cost of securities sold.

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.

Each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company’s ability and intent to hold

Free historical financial statements for Novocure Ltd.. See how revenue, income, cash flow, and balance sheet financials have changed over 32 quarters since 2016. Compare with NVCR stock chart to see long term trends.

Data imported from Novocure Ltd. SEC filings. Check original filings before making any investment decision.